Medi-Radiopharma Showcasing Innovation at EANM 2025 in Barcelona
The European Association of Nuclear Medicine (EANM) Congress is one of the most important annual gatherings in the field of nuclear medicine, molecular imaging, and radiopharmaceutical development. Each year, the event brings together leading experts, researchers, and companies to exchange knowledge, present scientific advances, and discuss the future of patient care.
For Medi-Radiopharma, EANM represents a unique opportunity to demonstrate its growing capabilities and commitment to innovation in radiopharmaceutical manufacturing and sterile fill-finish solutions. Over the years, participating at EANM has become a tradition, with the company continuously expanding its presence to reflect its evolution and growth within the global healthcare landscape.
The 2025 congress marks another milestone as Medi-Radiopharma exhibits at Booth #70 in Barcelona. The event serves as a platform to highlight the company’s broadened portfolio of services, including its AI-powered in silico protein design capabilities. This cutting-edge offering complements Medi-Radiopharma’s core expertise in cold kit production, radiopharmaceutical contract development and manufacturing (CDMO) services, and sterile drug product development.
EANM also provides invaluable insights into emerging trends through its extensive program of scientific abstracts, presentations, and educational sessions. For Medi-Radiopharma, these sessions are an essential way to understand where the industry is heading and to align future strategies with the evolving needs of clinicians, researchers, and patients worldwide.
As a company deeply committed to quality, collaboration, and patient outcomes, Medi-Radiopharma values the connections and partnerships nurtured through EANM. The congress reflects the collective effort required to advance molecular imaging, theranostics, and radiopharmaceutical innovation — all of which are vital to improving diagnostics and treatments for patients across the globe.
By consistently participating in EANM year after year, Medi-Radiopharma demonstrates its dedication to excellence, its readiness to embrace new technologies, and its role as a trusted partner in the international radiopharmaceutical community.